Verzenio vs Ibrance
A side-by-side look at two oncology medications advertised on TV. Informational only — not medical advice.
| US Verzenio | US Ibrance | |
|---|---|---|
| Generic name | abemaciclib | palbociclib |
| Drug class | CDK4/6 Inhibitor | CDK4/6 Inhibitor |
| Treats | HR+/HER2- breast cancer | HR+/HER2- breast cancer |
| Category | Oncology | Oncology |
| Manufacturer | Eli Lilly | Pfizer |
| Year approved | 2017 | 2015 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $85M | $80M |
| Common side effects | Diarrhea, Low blood counts, Fatigue, Blood clots | Low white blood cell count, Infections, Fatigue, Nausea |
Frequently asked questions
Is Verzenio or Ibrance better?
Neither is universally "better." Verzenio (abemaciclib) and Ibrance (palbociclib) are both used for oncology, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Verzenio and Ibrance?
Verzenio is a CDK4/6 Inhibitor made by Eli Lilly, while Ibrance is a CDK4/6 Inhibitor made by Pfizer. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Verzenio has the larger estimated TV advertising budget of the two.